Originally posted here: Clearmind Medicine Completed Type A Meeting with the FDA
Originally posted here: Clearmind Medicine Completed Type A Meeting with the FDA
Here is the original post: Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Excerpt from: PharmaTher Provides Update for Expected FDA Approval of Ketamine
Original post: Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory...
Here is the original post: Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
See original here: VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
Original post: AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi®...
Link: Parexel and Japanese Foundation for Cancer Research Announce Strategic Alliance
The rest is here: Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
Recent Comments